Several weeks into a run of US IPO delays, the anticipated 4Q calendar is facing increasing delays from problems hidden beneath reassuring headline indices.

For over a week, the VIX was well below 20, a level that would ordinarily put the IPO market firmly in “go” territory, said Evan Riley, head of ECM Americas at BNP Paribas.

Instead, conditions have grown trickier. Moves in rates and commodities made September difficult for investors to navigate, while sector rotations left performance uneven, Riley said. The mixed reception for recent IPOs has made investors more discerning about the next group of candidates.

Against this backdrop, higher sovereign bond yields have changed the calculation by offering an attractive fixed-income return without the risks attached to companies that have not previously operated in public markets, an accountant noted. The 10-year Treasury yield remains near a multi-decade high. Although markets largely expect the Federal Reserve to leave rates unchanged on October 28, the prospect of further tightening has not disappeared.

Developments in the Gulf, higher-for-longer oil prices and their implications for corporate costs have also contributed to caution, said Nick Williams, head of Americas ECM at Deutsche Bank.

“Below the surface” has become a very frequently used phrase to describe the single stock volatility and sector dispersion in Q3, said Stephane Gruffat, global head of ECM syndicate at Deutsche Bank.

There is still capacity among hedge funds and long-short investors, which can assess companies efficiently and provide demand at an appropriate valuation, he said. But securing broad mutual fund participation has become harder.

Mutual funds have become more disciplined and price-sensitive when valuing newer assets, particularly growth companies, Williams said, adding that they require greater conviction around fundamental value before committing capital.

The pipeline itself presents another problem: few of the companies seeking to list have given investors a compelling reason to own them, according to an investor. “There are a lot of IPOs launching that aren’t really must-own investments, and consequently there’s a lack of conviction among buyers,” the investor said.

Even familiar features of an offering are receiving a more skeptical interpretation. A large secondary component can increase the free float and improve liquidity in a strong market. In a cautious one, it prompts investors to ask why existing shareholders are selling so much, Williams of Deutsche Bank said.

The same shift applies to growth prospects; investors who might previously have paid for the possibility that a company could enter adjacent markets are now more likely to ask management to demonstrate that it can before paying for it upfront, he said.

Some candidates have continued to pursue valuations associated with conditions in the first half of the year. Bringing buyers and sellers back together may therefore require time as well as a lower price. Even then, getting an IPO priced is only the first test.

Some smaller IPOs have had softer aftermarkets mainly because there was insufficient aftermarket buying momentum, rather than active selling, Deutsche Bank’s Gruffat said.

Investors are also seeking a greater margin for error around company performance. An attractive entry price may help an issuer complete its offering, but it will do little for the wider calendar if the shares subsequently struggle.

A few straightforward transactions with conventional structures, fair pricing and reasonable aftermarket performance will help the market regain its footing, Gruffat said. In his view, IPO sentiment may have moved too far in a negative direction.

Still, one successful IPO would probably be insufficient, an ECM banker at a US investment bank said. Investors would gain more confidence from seeing companies with different profiles across several sectors list successfully and then trade higher.

“Not a lot of people want to be the first one through that door,” the banker said. Postponing can also be preferable to forcing an IPO through and risking another weak debut, he said.

November’s narrower window

Companies now face different versions of the same choice. Several candidates could perform well as public companies, but many remain willing to stay private rather than enter the market at a suboptimal time, said Matthew Kennedy, markets strategist at Renaissance Capital.

“It’s not like these are terrible market conditions,” Kennedy said. “These companies have the ability to cut the price and get the deal done if they wanted to. But apparently they don’t.”

Such degree of flexibility is contributing to a thinner immediate calendar. Even a reduced price, however, may remain above the valuation at which public investors are prepared to assume the risk.

For companies still considering 2026, decisions are increasingly being made from week to week. Some candidates have moved into the first quarter, while others are weighing whether to launch before the midterms or during the brief year-end windows that follow. Third-quarter results from close public comparables could help candidates establish a clearer valuation basis before proceeding.

Investors expect Q3 earnings to be strong. A further market rally may require either upgrades to results and outlook statements or clarity from the US midterms, Gruffat said.

The thinner November calendar could benefit companies prepared to move. Issuers with the right profile, completed investor meetings, and valuations the buyside is willing to support would face less competition for attention, the ECM banker said.

Anthropic could provide an exception to the caution holding back the wider calendar. Its scale and distinctive equity story may give it a route through a market that has proved more difficult for smaller candidates. Its outcome could affect the remaining window in two directions. A successful listing could help investors regain confidence that they can make money from new issues. Yet some could hold back from other deals while determining how much capital they might allocate to it.

Publicly filed candidates could move quickly once valuations become easier to define and predict. Risk appetite could also revive if investors who have spent recent months protecting their returns begin to underperform their benchmarks or peers and feel pressure to pursue additional gains.

But the possibility diminishes as December approaches. Sponsor-backed Medline was able to list late last year because it offered unusual scale and liquidity, as well as a relatively defensive business, the investor said. Smaller or less established candidates are unlikely to receive the same reception when portfolio managers are protecting their annual performance.

“Nobody is going to take a flyer on a USD 150m or USD 200m IPO that’s small, marginal and not particularly interesting,” the investor said.